<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03783702</url>
  </required_header>
  <id_info>
    <org_study_id>46384</org_study_id>
    <nct_id>NCT03783702</nct_id>
  </id_info>
  <brief_title>Pain Control Following Sinus Surgery</brief_title>
  <official_title>Efficacy of Non-Opioid Analgesics in the Management of Pain Following Endoscopic Sinus Surgery: A Multi-Institutional Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NorthShore University HealthSystem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the ongoing national opioid epidemic, an increased interest has developed in optimizing
      opioid prescribing practices of physicians, including otolaryngologists. Endoscopic sinus
      surgery (ESS) is one of the most commonly performed surgeries by otolaryngologists with over
      250,000 ESS's performed annually in the U.S. Multiple studies have shown that, compared to
      the amount patients actually consume, otolaryngologists prescribe a high quantity of opioids
      to patients recovering from ESS). It has been shown that these excess opioid medications
      contribute to prolonged use or abuse by the patient, family members, or friends. The purpose
      of this study is to better understand the pain management requirements of patients who
      undergo ESS for recurrent acute rhinosinusitis (RARS) or chronic rhinosinusitis (CRS).

      This prospective, randomized, multi-institutional controlled trial will aim to determine the
      degree to which pain following ESS can be adequately controlled by non-opioid medications. It
      will also determine whether post-ESS narcotic use can be avoided entirely, or at least
      significantly limited. Patients will be randomized into two groups, each of which will
      receive a stepwise analgesic regimen consisting of acetaminophen and oxycodone or
      acetaminophen and ibuprofen. Pain will be assessed daily using visual analog scales (VAS) and
      the Brief Pain Inventory (BPI).

      The results of this study will help to develop a standardized approach to pain management in
      the post-ESS setting and help to elucidate the role of non-opioid pain medications. The
      ultimate goal would be to positively affect opioid prescribing patterns among surgeons who
      perform ESS in order to significantly reduce the quantity of opioids prescribed to patients
      while continuing to adequately manage patients' pain.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized into one of two groups: one will receive acetaminophen and oxycodone while the other will receive acetaminophen, ibuprofen, and oxycodone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for preoperative visit (the day before surgery)</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for postoperative day 1</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for postoperative day 2</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for postoperative day 3</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for postoperative day 4</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for postoperative day 5</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for postoperative day 6</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain severity</measure>
    <time_frame>Average pain score will be collected for postoperative day 7</time_frame>
    <description>A 10-cm visual analog scale (VAS) will be used to assess pain severity.The VAS is a continuous, patient-reported outcome measure determined using a horizontal 100-mm scale ranging from &quot;no pain&quot; with a score of 0 to &quot;worst imaginable pain,&quot; corresponding to a score of 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication log</measure>
    <time_frame>Preoperative visit (the day before surgery) to postoperative day 7</time_frame>
    <description>Patients will keep a detailed log of any analgesics they take. The number of each time of medication will be counted and added to determine total medication consumption. This will be reported as an outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>BPI score will be collected at the preoperative visit</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>Average BPI score will be collected for postoperative day 1</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>Average BPI score will be collected for postoperative day 2</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>Average BPI score will be collected for postoperative day 3</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>Average BPI score will be collected for postoperative day 4</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>Average BPI score will be collected for postoperative day 5</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>Average BPI score will be collected for postoperative day 6</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Score</measure>
    <time_frame>Average BPI score will be collected for postoperative day 7</time_frame>
    <description>The BPI is a 15-item, validated patient-reported outcome measure used to assess pain severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected at the preoperative visit</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected for postoperative day 1</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected for postoperative day 2</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected for postoperative day 3</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected for postoperative day 4</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected for postoperative day 5</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected for postoperative day 6</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of epistaxis</measure>
    <time_frame>Epistaxis severity will be collected for postoperative day 7</time_frame>
    <description>The severity of epistaxis will be recorded using a VAS score ranging from &quot;No bleeding&quot; to &quot;continuous bleeding.&quot;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Sinusitis</condition>
  <condition>Opioid Use</condition>
  <condition>Opioid Abuse</condition>
  <condition>Narcotic Use</condition>
  <condition>Otolaryngologic Disease</condition>
  <condition>Postoperative Pain</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is ibuprofen (600mg tablet by mouth every 6 hours). Oxycodone (5mg tablet by mouth every 4 hours) will be the third-line medication to be used if acetaminophen and ibuprofen do not sufficiently control the pain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the control group will be asked to start with acetaminophen (650mg tablet by mouth every 6 hours) when they are in pain. If they still require additional analgesics, the second-line medication is oxycodone (5mg tablet by mouth every 4 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OxyCODONE 5 Mg Oral Tablet</intervention_name>
    <description>Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 Mg Oral Tablet</intervention_name>
    <description>Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen 650 MG Oral Tablet</intervention_name>
    <description>All patients will receive acetaminophen as the first-line analgesic.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  English-speaking

          -  Scheduled to undergo endoscopic sinus surgery for sinusitis (CRSwNP, CRSsNP, or RARS)

          -  Can commit to follow up for at least one postoperative visit

        Exclusion Criteria:

        Patients undergoing a septorhinoplasty (septoplasty permissible if patient will also
        undergo sinus surgery)

          -  Doyle splints to be used

          -  Alcohol or opioid use disorder

          -  History of chronic pain disorders

          -  Regular use of acetaminophen/NSAIDS (&gt;4x per week)

          -  Patients who use narcotics or neuromodulating drugs (e.g. gabapentin,
             nortriptyline)more than 2x per week on average.

          -  Gastrointestinal ulcers or bleeding

          -  Chronic kidney disease/known decreased renal function (estimated glomerular filtration
             rate &lt;60)

          -  Liver cirrhosis or other hepatic impairment

          -  Prior adverse reaction to opioids or NSAIDS

          -  Other contraindications to any drug classes in either group.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Noel F Ayoub, MD MBA</last_name>
    <phone>(650) 725-6500</phone>
    <email>nfa@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Hwang, MD</last_name>
    <email>hwangph@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noel F Ayoub, MD MBA</last_name>
      <email>nfa@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Peter H Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gnathan Carpenter, RN BSN</last_name>
    </contact>
    <investigator>
      <last_name>Joseph Raviv, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melanie Thompson, CCRP</last_name>
    </contact>
    <investigator>
      <last_name>Garret Choby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Einstein</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharan Shah</last_name>
    </contact>
    <investigator>
      <last_name>Waleed Abuzeid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Dorminy</last_name>
    </contact>
    <investigator>
      <last_name>Justin Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Derikvand</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Thamboo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bhattacharyya N. Ambulatory sinus and nasal surgery in the United States: demographics and perioperative outcomes. Laryngoscope. 2010 Mar;120(3):635-8. doi: 10.1002/lary.20777.</citation>
    <PMID>20058315</PMID>
  </reference>
  <reference>
    <citation>Schwartz MA, Naples JG, Kuo CL, Falcone TE. Opioid Prescribing Patterns among Otolaryngologists. Otolaryngol Head Neck Surg. 2018 May;158(5):854-859. doi: 10.1177/0194599818757959. Epub 2018 Feb 20.</citation>
    <PMID>29460670</PMID>
  </reference>
  <reference>
    <citation>Svider PF, Arianpour K, Guo E, Folbe E, Zuliani G, Lin H, Eloy JA, Folbe AJ. Opioid prescribing patterns among otolaryngologists: Crucial insights among the medicare population. Laryngoscope. 2018 Jul;128(7):1576-1581. doi: 10.1002/lary.27101. Epub 2018 Feb 15.</citation>
    <PMID>29446449</PMID>
  </reference>
  <reference>
    <citation>Mohan S, Bhattacharyya N. Opioids and the Otolaryngologist: An Ambulatory Assessment. Otolaryngol Head Neck Surg. 2018 Jul;159(1):29-34. doi: 10.1177/0194599818765125. Epub 2018 Mar 20.</citation>
    <PMID>29557264</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>December 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Peter Hwang</investigator_full_name>
    <investigator_title>Principal Investigator, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Otorhinolaryngologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

